SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is experiencing a sharp sell-off after reporting mixed Q4 earnings, where a revenue miss and conservative forward guidance overshadowed its profitability. The community is actively debating whether the market's strong negative reaction is an overdone response to broader fintech sector and macro credit concerns, or if it reflects justified apprehension regarding the company's cautious outlook.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group (CRDO) is surging after pre-announcing preliminary Q3 revenue significantly above prior guidance and consensus, coupled with a robust outlook for sequential growth into fiscal year 2027. The community is vigorously discussing this strong performance, highlighting its crucial role in the ongoing AI data center buildout and the massive capital expenditure increases from hyperscalers, expecting continued upward momentum.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is in focus following the abrupt departure of its CFO and general counsel amidst an accounting review and delayed regulatory filings, triggering a severe sell-off. The community is debating whether the IT infrastructure provider's over 50% stock drop is an extreme overreaction and a buying opportunity, or a justified response to serious governance concerns.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

FISV is trending intensely ahead of its earnings, with the community sharply divided between those anticipating a strong rebound fueled by perceived undervaluation, recent institutional accumulation, and new leadership's strategic moves, and those fearing another significant drop due to past disappointments, heavy put option activity, and ongoing fintech sector concerns.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending after the FDA issued a Complete Response Letter for its RGX-121 gene therapy for Hunter syndrome, citing concerns with trial design, external controls, and surrogate endpoints, amplifying broader sector scrutiny on gene therapies. The community is sharply divided, with some anticipating significant further declines and others believing the company's other pipeline assets retain substantial long-term value.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is trending due to recent exchange listings and its expansion to the Solana blockchain, significantly increasing its accessibility and multi-chain utility. The community is actively discussing its AI agent-powered utility on the Base ecosystem, with many anticipating a significant price appreciation while others warn of potential volatility.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending following its robust Q4 earnings beat, though a mixed Q1 outlook is fueling debate among investors between short-term caution and long-term optimism regarding its pivotal role in advanced AI and data center packaging, bolstered by strategic investments and CHIPS Act funding.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending lower after its latest earnings report, with disappointing Q1 guidance overshadowing beats on Q4 figures and positive long-term projections. The community is actively debating whether the significant price drop is an overreaction or signals deeper concerns about AI's impact on the gig economy and the company's future growth trajectory.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is generating significant buzz following its Nasdaq listing, a recent financing round, and a reverse stock split, sparking an active community debate on the revolutionary potential of its SAT-3247 drug for Duchenne muscular dystrophy against concerns regarding dilution and the early stage of its clinical development.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

CRO is trending following news of Trump Media's ($DJT) partnership with crypto.com/us for digital token distribution on the Cronos chain, with discussions also highlighting its potential inclusion and significant weighting in a proposed Crypto ETF. This development is driving considerable community debate, with some anticipating substantial growth while others express skepticism about the coin's future trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Does the Market Think About MetaVia Inc?

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering...

MetaVia Stock Slides After Pricing Public Offering

(RTTNews) - MetaVia Inc. (MTVA) shares traded at $3.4050, down 39.03% or $2.18 lower, after the company announced the pricing of an $8.1 million underwritten public offering...

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering PR Newswire CAMBRIDGE, Mass., Jan. 15, 2026...

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic...

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference PR Newswire CAMBRIDGE, Mass., Dec. 29...

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire CAMBRIDGE, Mass., Dec. 22, 2025 CAMBRIDGE, Mass...

<ul class="summary-bullets"><li>CIMG will implement a 20-for-1 reverse stock split, effective December 5.</li><li>MetaVia’s 1-for-11 reverse stock split of common stock will come into effect on December 4.</li><li>Treasure Global said its 1-for-20 reverse stock split of common stock will come into effect on December 5.</li></ul>&nbsp;Companies often use reverse stock splits to maintain their stock exchange listing, as major exchanges require the stock’s price to trade above $1. Falling below that level for 30 straight trading days triggers a deficiency notice, and the company is given a limited window to lift the share price.A reverse split raises the stock’s price by reducing the share count, helping the company regain compliance and avoid delisting.On Friday, four stocks will begin trading post a reverse split:CIMG Inc. (IMG), a digital health and sales development company, is set for a 20-for-1 reverse stock split, which takes effect on December 5. Post-split, CIMG’s stock will continue trading on Nasdaq under the symbol “IMG.” The reverse split will reduce the company’s outstanding shares to around 15.5 million from approximately 310 million.The reverse split also applies to stock options and warrants, with fractional shares rounded up to the nearest whole share.On Thursday, <a href="https://stocktwits.com/symbol/IMG">IMG stock</a> was down 10%, while retail sentiment on Stocktwits remained in the ‘bearish’ zone over the past 24 hours.MetaVia Inc. (MTVA), a clinical-stage biotech company focused on cardiometabolic diseases, announced a 1-for-11 reverse stock split of its common stock, effective December 4, post-market hours.Starting December 5, MetaVia’s shares will trade on Nasdaq on a split-adjusted basis under the symbol “MTVA.” The reverse split reduces outstanding shares from around 25.4 million to 2.3 million.<a href="https://stocktwits.com/symbol/MTVA">MTVA stock</a> gained around 7% on Thursday, while retail sentiment on Stocktwits remained in the ‘bearish’ territory over the past 24 hours.Treasure Global Inc.&nbsp;(TGL) said its 1-for-20 reverse stock split of common stock will come into effect on December 5. The company’s shares will continue trading on Nasdaq under the symbol “TGL” on a split-adjusted basis.The reverse split reduces outstanding shares from around 17 million to 848,100 and aims to help the company regain compliance with Nasdaq’s $1 minimum bid price requirement.<a href="https://stocktwits.com/symbol/TGL">TGL shares</a> were up marginally on Thursday as retail sentiment on Stocktwits remained ‘bullish’ over the past 24 hours.&nbsp;Tactical Resources Corp.’s (USREF) 5-for-1 share consolidation will come into effect on December 5. The action will reduce the total outstanding shares to around 7.35 million.<a href="https://stocktwits.com/symbol/USREF">USREF shares</a> had climbed 1% as retail sentiment on Stocktwits remained in the ‘bullish’ zone.For updates and corrections, email newsroom[at]stocktwits[dot]com.

IMG, MTVA, USREF, TGL: These Four Stocks Trade Ex-Reverse Split On Friday

A reverse split raises the stock’s price by reducing the share count, helping the company regain compliance and avoid delisting.

Equity

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

MetaVia Inc. Announces 1-for-11 Reverse Stock Split MetaVia Inc. Announces 1-for-11 Reverse Stock Split PR Newswire CAMBRIDGE, Mass., Dec. 2, 2025 CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire...

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting 2025

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting 2025 MetaVia Presents Positive New Phase 2a Data on Vanoglipel...

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

MetaVia Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

MTVA
MetaVia Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest MTVA News

MTVAMetaVia Inc.